We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 31, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Johnson & Johnson (JNJ - Free Report) , Boston Scientific Corp. (BSX - Free Report) and Armanino Foods of Distinction, Inc. (AMNF - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Amazon, J&J and Boston Scientific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Amazon.com, Inc., Johnson & Johnson and Boston Scientific Corp., as well as a micro-cap stock Armanino Foods of Distinction, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Amazon.com's shares have outperformed the Zacks Internet - Commerce industry over the year-to-date period (+27.2% vs. +25.4%). The company is gaining on solid Prime momentum owing to ultrafast delivery services and strong content portfolio. Strengthening relationships with third-party sellers is a positive.
Amazon.com's expanding global presence and solid momentum among the small and medium businesses, remain a plus. Growing adoption of AWS is aiding Amazon's cloud dominance. Deepening focus on generative AI is a major plus. Also, improving Alexa skills along with robust smart home products offerings are tailwinds. Growing capabilities in grocery, pharmacy, healthcare and autonomous driving are other positives.
However, macroeconomic challenges remain headwinds. Amazon issued weak third-quarter 2024 revenue guidance due to the changing shopping pattern of consumers, which is a negative.
Shares of Johnson & Johnson have gained +3.6% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry's gain of +19.1%. The company beat third-quarter estimates for earnings and sales. Its Innovative Medicine unit is performing at above-market levels. Growth is being driven by existing products like Darzalex, Tremfya and Erleada and also continued uptake of new launches, including Spravato, Carvykti and Tecvayli.
J&J is making rapid progress with its pipeline and line extensions with important readouts lined up for 2025. However, sales in the MedTech segment have been lower than expected due to Asia-Pacific headwinds, specifically in China.
J&J faces the upcoming patent expiration of the blockbuster drug Stelara in January 2025, which will hurt the drug's sales. J&J is incurring huge legal expenses due to the pending lawsuits related to its talc products.
Boston Scientific's shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+45.9% vs. +15.3%). The company is seeing strength across target markets despite macroeconomic concerns, currency headwinds and related cost inflation. Strong worldwide demand for its MedSurg and Structural Heart lines, traction in United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important drivers.
The Pain and Brain franchisees are expected to gain solid traction in 2024 banking on strong execution of core growth strategies. The Electrophysiology arm continues to gain momentum on sustained adoption of FARAPULSE PFA. The 2024 guidance indicating strong growth over 2023 builds confidence in the stock.
On the flip side, mounting costs due to worldwide geopolitical issues are major concerns. FX headwinds continue to largely offset the company's performance.
Shares of Armanino Foods of Distinction have outperformed the Zacks Food - Miscellaneous industry over the year-to-date period (+51.5% vs. +1.1%). This microcap company with market capitalization of $224.1 million presents a compelling investment case, driven by record-breaking financial performance, strong cash reserves and market dominance in key categories.
Third-quarter 2024 saw Armanino Foods' highest-ever sales and profits, with nine-month net sales growing 7% year over year to $50.9 million and a 65% rise in pre-tax income, boosted by improved margins. The company's profitability, driven by cost-cutting and efficiency gains, has supported an 81% quarterly net income increase.
With $24.3 million in cash and a steady dividend policy, AMNF is positioned for growth without tapping its credit line. Its 65% share in food service pesto and expansion into new U.S. retail regions underscore its brand strength. Focused on product innovation and operational efficiency, Armanino Foods is set for growth and future acquisitions, enhancing shareholder value.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction
For Immediate Release
Chicago, IL – October 31, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Johnson & Johnson (JNJ - Free Report) , Boston Scientific Corp. (BSX - Free Report) and Armanino Foods of Distinction, Inc. (AMNF - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Amazon, J&J and Boston Scientific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Amazon.com, Inc., Johnson & Johnson and Boston Scientific Corp., as well as a micro-cap stock Armanino Foods of Distinction, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Amazon.com's shares have outperformed the Zacks Internet - Commerce industry over the year-to-date period (+27.2% vs. +25.4%). The company is gaining on solid Prime momentum owing to ultrafast delivery services and strong content portfolio. Strengthening relationships with third-party sellers is a positive.
Amazon.com's expanding global presence and solid momentum among the small and medium businesses, remain a plus. Growing adoption of AWS is aiding Amazon's cloud dominance. Deepening focus on generative AI is a major plus. Also, improving Alexa skills along with robust smart home products offerings are tailwinds. Growing capabilities in grocery, pharmacy, healthcare and autonomous driving are other positives.
However, macroeconomic challenges remain headwinds. Amazon issued weak third-quarter 2024 revenue guidance due to the changing shopping pattern of consumers, which is a negative.
(You can read the full research report on Amazon.com here >>>)
Shares of Johnson & Johnson have gained +3.6% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry's gain of +19.1%. The company beat third-quarter estimates for earnings and sales. Its Innovative Medicine unit is performing at above-market levels. Growth is being driven by existing products like Darzalex, Tremfya and Erleada and also continued uptake of new launches, including Spravato, Carvykti and Tecvayli.
J&J is making rapid progress with its pipeline and line extensions with important readouts lined up for 2025. However, sales in the MedTech segment have been lower than expected due to Asia-Pacific headwinds, specifically in China.
J&J faces the upcoming patent expiration of the blockbuster drug Stelara in January 2025, which will hurt the drug's sales. J&J is incurring huge legal expenses due to the pending lawsuits related to its talc products.
(You can read the full research report on Johnson & Johnson here >>>)
Boston Scientific's shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+45.9% vs. +15.3%). The company is seeing strength across target markets despite macroeconomic concerns, currency headwinds and related cost inflation. Strong worldwide demand for its MedSurg and Structural Heart lines, traction in United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important drivers.
The Pain and Brain franchisees are expected to gain solid traction in 2024 banking on strong execution of core growth strategies. The Electrophysiology arm continues to gain momentum on sustained adoption of FARAPULSE PFA. The 2024 guidance indicating strong growth over 2023 builds confidence in the stock.
On the flip side, mounting costs due to worldwide geopolitical issues are major concerns. FX headwinds continue to largely offset the company's performance.
(You can read the full research report on Boston Scientific here >>>)
Shares of Armanino Foods of Distinction have outperformed the Zacks Food - Miscellaneous industry over the year-to-date period (+51.5% vs. +1.1%). This microcap company with market capitalization of $224.1 million presents a compelling investment case, driven by record-breaking financial performance, strong cash reserves and market dominance in key categories.
Third-quarter 2024 saw Armanino Foods' highest-ever sales and profits, with nine-month net sales growing 7% year over year to $50.9 million and a 65% rise in pre-tax income, boosted by improved margins. The company's profitability, driven by cost-cutting and efficiency gains, has supported an 81% quarterly net income increase.
With $24.3 million in cash and a steady dividend policy, AMNF is positioned for growth without tapping its credit line. Its 65% share in food service pesto and expansion into new U.S. retail regions underscore its brand strength. Focused on product innovation and operational efficiency, Armanino Foods is set for growth and future acquisitions, enhancing shareholder value.
(You can read the full research report on Armanino Foods of Distinction here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.